Overall Metabolic Profile and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder. Reviewed by the ExomeDNA Science Team.
What is the overall metabolic profile?
The overall metabolic profile captures the complex biochemical landscape governing how the body processes, transports, and clears a broad array of molecules—including fatty acids, amino acids, glucose, bile conjugates, and xenobiotic compounds. Unlike single-biomarker traits that reflect one pathway, a broad metabolic trait captures the composite influence of many physiological systems operating simultaneously. The result is a distributed phenotype shaped by dozens of genetic loci spanning liver enzyme activity, renal transporter function, mitochondrial cycling, and nuclear receptor signaling.
Genome-wide association studies designed to capture metabolic trait variation broadly have identified signals across a remarkably diverse functional gene set, from organic cation transporters in hepatocytes to fatty acid elongases in the endoplasmic reticulum. This breadth reflects the genuine biological complexity of metabolic regulation: what clinicians measure as metabolic health emerges from a distributed network of upstream genetic influences rather than a single regulatory bottleneck. Understanding which pathways carry the strongest genetic signal can frame more precise questions about metabolic risk and resilience.
This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. ExomeDNA's genetic reports are for wellness and educational purposes only.
The genetics behind metabolic function
Thirty-seven high-confidence GWAS credible sets—each with established locus-to-gene linkage—implicate a functionally diverse set of genes in metabolic trait variation. The signal spans at least six distinct biological subsystems, collectively mapping the distributed genetic architecture of metabolic regulation.
Hepatic transport and organic cation clearance. SLC22A1 (OCT1), ranked first among the top loci (L2G 0.92), encodes the organic cation transporter 1 localized to the basolateral membrane of hepatocytes. OCT1 is the primary uptake transporter for organic cations entering the liver, including metformin, choline, and numerous bile acid intermediates. Variants that reduce OCT1 function alter hepatic uptake kinetics, affecting downstream metabolite levels in circulation and influencing how systemically measured metabolic markers relate to hepatic processing capacity.
Renin-angiotensin physiology. ACE (L2G 0.92) encodes angiotensin-converting enzyme, which converts angiotensin I to the vasoactive angiotensin II. The ACE insertion/deletion polymorphism is one of the most extensively studied human genetic variants; it modulates blood pressure, fluid balance, and inflammatory tone in ways that intersect deeply with metabolic syndrome components. ACE signal in a broad metabolic GWAS reflects the integration of cardiovascular and metabolic physiology at the genetic level.
Amino acid biosynthesis and one-carbon metabolism. PHGDH (L2G 0.91) encodes phosphoglycerate dehydrogenase, the rate-limiting enzyme in the serine biosynthesis pathway. Serine is a precursor for glycine, phospholipids, the folate one-carbon cycle, and sphingolipids. Variants reducing PHGDH activity can alter serine availability across these downstream pathways, with measurable consequences for metabolomics panels that capture amino acid and lipid metabolite levels simultaneously.
Purinergic and adenosine signaling. NT5E (CD73, L2G 0.91) encodes ecto-5'-nucleotidase, the enzyme converting extracellular AMP to adenosine. Adenosine acts as a cellular energy sensor, modulating insulin sensitivity, lipid mobilization, and inflammatory signaling in adipose and hepatic tissue through purinergic receptor pathways. Variants in NT5E that alter CD73 activity influence the purinergic tone connecting energy-sensing to metabolic regulation.
Bile and drug conjugation. UGT1A1 (L2G 0.91) encodes UDP-glucuronosyltransferase 1A1, which conjugates bilirubin and numerous drugs and metabolic intermediates to glucuronic acid for biliary and urinary excretion. The UGT1A1*28 promoter variant reducing enzyme expression underlies Gilbert syndrome and modifies systemic clearance of multiple metabolically relevant compounds, illustrating how conjugation capacity shapes circulating metabolite profiles.
Omega-3 lipid elongation and biological aging. ELOVL2 (L2G 0.86) encodes fatty acid elongase 2, catalyzing the elongation of long-chain polyunsaturated fatty acids toward DHA (22:6n-3) and EPA (20:5n-3). Dietary omega-3 availability and endogenous DHA synthesis both flow through ELOVL2, linking this locus to membrane composition, inflammatory tone, and lipid metabolomics measures. Independently, ELOVL2 promoter methylation is among the most reproducible molecular aging clocks identified in the human epigenome, coupling metabolic genetics to biological age trajectories.
Xenobiotic and dietary chemical sensing. AHR (L2G 0.74) encodes the aryl hydrocarbon receptor, a ligand-activated transcription factor that induces CYP1A1, CYP1A2, and a suite of metabolizing enzymes in response to environmental chemicals, dietary indoles, and microbiome-derived tryptophan metabolites. AHR signaling modulates the detoxification capacity available to each individual and intersects with gut microbiome composition in ways that influence systemic metabolic phenotypes.
GWAS locus breadth: Variants across 37 independent credible genomic loci—spanning hepatic transport, renin-angiotensin physiology, serine biosynthesis, purinergic signaling, bile conjugation, lipid elongation, and xenobiotic sensing—contribute collectively to broad metabolic trait variation captured across large population cohorts.
SLC22A1 clinical context: Common variants in SLC22A1 that reduce OCT1 activity are carried by 10–20% of individuals of European ancestry. These variants alter hepatic uptake kinetics for a range of organic cations, including metformin—a finding that has informed pharmacogenomics research on metformin response in type 2 diabetes management contexts.
ELOVL2 dual biology: ELOVL2 is simultaneously a key enzyme in omega-3 DHA synthesis and one of the most reproducible epigenetic aging clock genes identified to date. Methylation changes at the ELOVL2 locus predict biological age independently of chronological age across diverse human cohort studies.
What the research says
Genome-wide association studies of broad metabolic trait panels (et al., 2009; PMID 19060910 and et al., 2011; PMID 21886157) identified genetic loci spanning multiple metabolic subsystems, establishing that the genetic architecture of metabolic health is profoundly distributed rather than pathway-concentrated. The 37 credible sets in this trait reflect a dense signal across diverse functional gene classes—an architecture consistent with the regulatory redundancy and cross-pathway integration that characterizes metabolic physiology.
The mechanistic diversity across top-ranked genes—hepatic transporters, angiotensin enzymes, serine biosynthesis, adenosine signaling, bile conjugation, fatty acid elongation, and xenobiotic sensing—underscores that metabolic health as a phenotype integrates signals from physiological systems that clinicians often assess independently. This genetic finding reflects their shared upstream regulation in population variation.
Research base: Moderate.
How your metabolic profile affects you
Because higheris is contextdependent for this trait, no single directionality applies. The metabolic traits captured by this GWAS reflect variation across multiple physiological axes—some individual-level measures may run higher or lower than population averages depending on which loci carry the strongest personal influence. The appropriate interpretation is a map of which subsystems carry the greatest genetic weight rather than a single directional score.
| Pathway | Representative gene | Functional consequence |
|---|---|---|
| Hepatic organic cation clearance | SLC22A1 | Altered metabolite and drug uptake kinetics |
| Blood pressure and inflammatory tone | ACE | Angiotensin II-mediated metabolic effects |
| Serine and one-carbon metabolism | PHGDH | Downstream effects on lipid, amino acid, folate cycles |
| Purinergic energy sensing | NT5E | Adenosine-mediated insulin and lipid modulation |
| Bile and drug conjugation | UGT1A1 | Bilirubin and metabolite clearance capacity |
| Omega-3 DHA synthesis | ELOVL2 | Membrane composition and inflammatory lipid mediators |
| Xenobiotic and dietary sensing | AHR | Detoxification capacity and microbiome-diet interaction |
This page is informational only. For health decisions, consult a qualified clinician.
Working with your profile
The distributed genetic architecture of broad metabolic function means that no single intervention targets all contributing pathways simultaneously. Instead, the research literature supports pathway-aware approaches: optimizing dietary fatty acid intake to support ELOVL2-mediated DHA synthesis; attending to hepatic load for individuals with variants in SLC22A1; monitoring blood pressure and inflammatory markers as ACE variant effects compound through the renin-angiotensin axis.
Because contextdependent higheris applies, this profile is best interpreted as identifying which metabolic subsystems carry the strongest genetic influence—a starting point for more targeted physiological inquiry and for more personalized conversations with clinicians about which pathways merit closest attention.
Related traits and genes
- Serum uric acid — SLC22A1 and SLC2A9 as shared transporters across purine and organic cation handling
- Bilirubin levels — UGT1A1 as the primary conjugation enzyme, with Gilbert syndrome as the common phenotype extreme
- Omega-3 fatty acid levels — ELOVL2 as the biosynthetic bottleneck for endogenous DHA and EPA production
- Blood pressure — ACE insertion/deletion as one of the best-characterized metabolic-cardiovascular genetic overlaps
Frequently asked questions
What does SLC22A1 do in metabolic regulation?
SLC22A1 encodes OCT1 (organic cation transporter 1), located on the basolateral membrane of hepatocytes. OCT1 imports organic cations—including metformin, choline, and bile acid intermediates—from portal blood into the liver for processing or excretion. Variants reducing OCT1 function alter the kinetics of hepatic clearance for these compounds, affecting downstream circulating metabolite levels. OCT1 variants have been studied in the context of metformin pharmacokinetics, with evidence that reduced-function alleles blunt hepatic metformin accumulation and downstream glucose-lowering capacity.
How does ACE connect to metabolic traits?
ACE converts angiotensin I to angiotensin II, a vasoactive peptide that regulates blood pressure, fluid balance, aldosterone secretion, and systemic inflammatory tone. These functions intersect with metabolic syndrome components—elevated blood pressure, insulin resistance, and dyslipidemia—through shared inflammatory and hemodynamic pathways. The ACE insertion/deletion variant is among the most extensively studied cardiovascular-metabolic genetics polymorphisms, with population effects on plasma ACE activity ranging approximately twofold between DD and II homozygotes.
What is the biological significance of PHGDH in metabolism?
PHGDH catalyzes the first committed step in the serine biosynthesis pathway, converting 3-phosphoglycerate to 3-phosphohydroxypyruvate. Serine is a precursor for glycine, phospholipids, sphingolipids, and the folate one-carbon cycle that drives nucleotide synthesis and methylation reactions. Variants reducing PHGDH activity can alter serine availability across these downstream pathways, with measurable consequences for metabolomics panels that capture amino acid and lipid metabolite levels simultaneously.
Why does ELOVL2 matter for both metabolism and aging?
ELOVL2 elongates C20 and C22 polyunsaturated fatty acids toward DHA (22:6n-3) and EPA (20:5n-3), making it the enzymatic bottleneck for endogenous omega-3 synthesis. Individuals with reduced-function variants may show lower circulating DHA despite adequate dietary intake, since dietary omega-3s only partially compensate for diminished endogenous elongation capacity. Separately, cytosine methylation at the ELOVL2 promoter undergoes highly reproducible age-dependent changes, making it one of the strongest single-gene predictors of biological age across human cohort studies—linking metabolic genetics to epigenetic aging biology through the same locus.
How should contextdependent higheris be interpreted for this trait?
When a trait is context_dependent, no single direction of genetic influence is uniformly advantageous or disadvantageous. For broad metabolic traits, this reflects the reality that individual metabolic loci may confer different consequences depending on physiological context. For example, UGT1A1 reduced-function variants lower bilirubin conjugation capacity—a disadvantage in drug clearance but potentially protective through bilirubin's antioxidant properties at moderate levels. The appropriate interpretation is a nuanced assessment of which pathways are most genetically influential, rather than a simple high/low directional score.
This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. ExomeDNA's genetic reports are for wellness and educational purposes only.